Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

by Ahmed, T., Allayous, C., Ascierto, P.A, Carlino, M., Dimitriou, F., Gerard, C., Johnson, D.B, Lebbe, C., Lo, S., Long, G., Mangana, J., Menzies, A., Michielin, O., Pires da Silva, I., Trojanello, C., Zakria, D., Zimmer, L.
Published 2022